Medical aesthetics company InMode (INMD) issued lighter-than-expected earnings guidance for 2023, sending INMD stock into the red early Tuesday.
For the year, InMode expects to earn $2.58-$2.60 per share, below expectations for $2.64, according to FactSet. The company also predicted to $525 million to $530 million in sales, above calls for $524 million.
In premarket trading on the stock market today, INMD stock slumped 1.4% near 33.50.
During the fourth quarter, sales climbed 21% to $133.6 million and adjusted profit surged 22% to 78 cents a share. Both metrics topped forecasts for $129.7 million and 67 cents, respectively.
More to follow.
Follow Allison Gatlin on Twitter at @IBD_AGatlin.
YOU MAY ALSO LIKE:
The Cream Of The Crop: 5 Biotech Stocks That Outrank 98% Of All Stocks
Teva Plots Its Knockoff Of Axsome’s New Depression Drug, Sending The Biotech Sprawling
Watch IBD’s Investing Strategies Show For Actionable Market Insights
Get Timely Buy & Sell Alerts With IBD Leaderboard
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
#InMode #Slumps #Light #Earnings #Outlook #Quarterly #Beat